Altered circulating Tregs and their functional cytokines in hypertensive patients with or without left ventricular hypertrophy

Abstract Background:Left ventricular hypertrophy (LVH) is the most common target organ damage in hypertension. In addition to the increased left ventricular afterload, immune injury participates in LVH pathogenesis. CD4+CD25+Foxp3+ regulatory T lymphocytes (Tregs) are a T cell subset with immunomodulatory effects; abnormal Treg numbers or functions can cause immune disorders. This study aimed to explore the role of Tregs in LVH by investigating circulating Tregs and associated cytokine levels in hypertensive patients with LVH.Methods:Blood samples were collected from 69 healthy individuals (control group, CG), 91 hypertensive patients with LVH (LVH group) and 83 hypertensive patients without LVH (essential hypertension, EH group). Circulating Tregs and associated cytokines were measured by flow cytometry and enzyme-linked immunosorbent assays, respectively.Results:Circulating Tregs were significantly lower in EH and LVH patients than in CG subjects. The circulating Treg level was lower in LVH patients than in EH patients. No correlation between blood pressure regulation and Treg levels was found in EH or LVH patients. Furthermore, circulating Tregs in postmenopausal females were lower than those in males among LVH patients. Additionally, serum IL-10 and transforming growth factor (TGF)-β1 were decreased in EH and LVH patients, and the serum IL-6 level was significantly increased in LVH patients. Circulating Tregs were negatively correlated with CK, LDL, apoB, high-sensitivity C-reactive protein and left ventricular mass index values.Conclusion:Our study is the first to demonstrate the significantly decreased circulating Treg proportion in LVH patients. The protective effect of Tregs in LVH is independent of blood pressure regulation. The functional Treg cytokines IL-6, IL-10 and TGF-β1 participate in this immunomodulatory process.Trial registration: The study was approved by the Institutional Medical Ethics Committee of the Second Xiangya Hospital of Central South University (2018/No.046).

Download Full-text

Association Between TGF-β Gene Polymorphism and Left Ventricular Hypertrophy in Essential Hypertension

Hypertension ◽

10.1161/hyp.36.suppl_1.704 ◽

2000 ◽

Vol 36 (suppl_1) ◽

pp. 704-704

Author(s):

Montserrat Enjuto ◽

Pablo Inigo ◽

Antonio Francino ◽

Elisenda Gomez-Angelats ◽

Josep M Campistol Alejandro ◽

...

Keyword(s):

Blood Pressure ◽

Essential Hypertension ◽

Left Ventricular Hypertrophy ◽

Gene Polymorphisms ◽

Ventricular Hypertrophy ◽

Left Ventricular Mass Index ◽

Left Ventricular ◽

Two Dimensional ◽

Hypertensive Patients ◽

Tgf Β1

P61 The aim of the study was to evaluate the possible association between two TGF-β1 gene polymorphisms and left ventricular hypertrophy in a group of essential hypertensive patients (EH). Ninety-three non treated EH underwent 24-hour ambulatory blood pressure, two-dimensional guided M-mode echocardiography in order to measure left ventricular mass index (LVMI), and TGF-β1 Leu 10 /Pro and Arg 25 /Pro polymorphism genotyping. As shown in the table, 24-h SBP and DBP were significantly higher in homozygous patients for the Arg 25 allele of the TGF-β1 gene. Likewise, homozygous patients for the Leu 10 allele and homozygous patients for the Arg 25 allele of the TGF-β1 gene had significanlty higher LVMI. We conclude that these TGF-β1 gene polymorphisms are associated with the severity of blood pressure and left ventricular hypertrophy in EH patients.

Download Full-text

Left Ventricular Hypertrophy in Hypertensive Patients with Autosomal Dominant Polycystic Kidney Disease: Influence of Blood Pressure and Humoral and Neurohormonal Factors

American Journal of Nephrology ◽

10.1159/000013583 ◽

2000 ◽

Vol 20 (3) ◽

pp. 193-200 ◽

Cited By ~ 25

Author(s):

Alberto Martinez-Vea ◽

F. Alfredo Valero ◽

Alfredo Bardaji ◽

Cristina Gutierrez ◽

Montse Broch ◽

...

Keyword(s):

Blood Pressure ◽

Kidney Disease ◽

Left Ventricular Hypertrophy ◽

Polycystic Kidney Disease ◽

Ventricular Hypertrophy ◽

Autosomal Dominant ◽

Left Ventricular ◽

Polycystic Kidney ◽

Hypertensive Patients ◽

Autosomal Dominant Polycystic Kidney

Download Full-text

Blood Pressure Control, Left Ventricular Hypertrophy and Treatment Practice Among Hypertensive Patients in Ethiopia

International Journal of General Medicine ◽

10.2147/ijgm.s273668 ◽

2020 ◽

Vol Volume 13 ◽

pp. 903-916

Author(s):

Daniel Gebrehawaria Kinfe ◽

Gebretsadik Berhe ◽

Kibreab Gidey ◽

Gebre Teklemariam Demoz

Keyword(s):

Blood Pressure ◽

Left Ventricular Hypertrophy ◽

Blood Pressure Control ◽

Ventricular Hypertrophy ◽

Pressure Control ◽

Left Ventricular ◽

Hypertensive Patients ◽

Treatment Practice

Download Full-text

P0152EFFECT OF LOSARTAN ON AMBULATORY SHORT-TERM BLOOD PRESSURE VARIABILITY AND CARDIOVASCULAR REMODELING IN HYPERTENSIVE PATIENTS ON HEMODIALYSIS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfaa142.p0152 ◽

2020 ◽

Vol 35 (Supplement_3) ◽

Author(s):

Koichi Azuma

Keyword(s):

Blood Pressure ◽

Treatment Group ◽

Plasma Levels ◽

Inhibitory Effect ◽

Left Ventricular ◽

Control Treatment ◽

Control Group ◽

Short Term ◽

Hypertensive Patients ◽

Cardiovascular Remodeling

Abstract Background and Aims Previous studies have shown increases in ambulatory short-term blood pressure (BP) variability to be related to cardiovascular disease. In this study, we examined whether an angiotensin II type 1 receptor blocker losartan would improve ambulatory short-term BP variability in hypertensive patients on hemodialysis. Method 40 hypertensive patients on hemodialysis therapy were randomly assigned to the losartan treatment group (n=20) or the control treatment group (n=20). At baseline and 6 and 12 months after the treatment, 24-h ambulatory BP monitoring was performed. Echocardiography and measurements of brachial-ankle pulse wave velocity (baPWV) and biochemical parameters were also performed before and after therapy. Results After 6- and 12-months of treatment, nighttime short-term BP variability, assessed on the basis of the coefficient of variation of ambulatory BP, was significantly decreased in the losartan group, but remained unchanged in the control group. Compared with the control group, losartan significantly decreased left ventricular mass index (LVMI), baPWV, and the plasma levels of brain natriuretic peptide and advanced glycation end products (AGE). Furthermore, multiple regression analysis showed significant correlations between changes in LVMI and changes in nighttime short-term BP variability, as well as between changes in LVMI and changes in the plasma levels of AGE. Conclusion These results suggest that losartan is beneficial for the suppression of pathological cardiovascular remodeling though its inhibitory effect on ambulatory short-term BP variability during nighttime.

Download Full-text